Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Quirino Lai et al.|The Lancet Oncology|2023Cited by 184
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given lateAdriano Pellicelli, M. Angélico, Marzia Montalbano et al.|Digestive and Liver Disease|2014Cited by 103
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysisMaria Guarino, Andrea Casadei‐Gardini, Luca Viganò et al.|Digestive and Liver Disease|2018Cited by 61